Newsletter

Click here to join
our newsletter.

Company Calendar

Highlights and Events.


March 19th 2018 - March 23rd 2018

Frédéric Triebel speaks on the subject:
"LAG-3: Identification & Validation of the Next Generation Checkpoint Pathway"

May 16th 2018 - May 18th 2018
May 24th 2018 - May 25th 2018

Frédéric Triebel speaks on the subject:

“Two ACTIve Immunotherapies in melanoma (TACTI-mel): results of a phase I trial with metastatic melanoma patients treated with a soluble LAG-3 receptor (LAG-3Ig or eftilagimod alpha) as an antigen presenting (APC) activator combined with pembrolizumab.”